Baldero, Melisa E.
HRN: 23-48-53 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/29/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
11/29/2023
12/06/2023
IV
500mg
Q8
G1P0 40 5/7 Weeks AOG; IUFD
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes